AnHeart Therapeutics receives FDA breakthrough therapy designation for taletrectinib in ROS1 positive non-small-cell lung cancer

AnHeart Therapeutics

3 August 2022 - FDA breakthrough designation reinforces significant unmet need in the treatment of this highly aggressive cancer.

AnHeart Therapeutics today announced that the U.S. FDA has granted breakthrough therapy designation to its investigational ROS1 inhibitor taletrectinib for the treatment of adult patients with advanced or metastatic ROS1 positive non-small-cell lung cancer who are ROS1 tyrosine kinase inhibitor treatment naïve or previously treated with crizotinib.

Read AnHeart Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track